Treatments for Adenocarcinoma of Renal Cells

 Treatments for Adenocarcinoma of Renal Cells

Drugs used to treat Adenocarcinoma of Renal Cells

 

medroxyprogesterone 

bevacizumab

Proleukin

lenvatinib

sorafenib

axitinib

cabozantinib

everolimus

Lenvima

Torisel

sunitinib

pazopanib

ipilimumab

Avastin

Yervoy

Nexavar

Afinitor

Cabometyx

pembrolizumab

nivolumab

Opdivo

Keytruda

Inlyta

Votrient

Sutent

Welireg

Bavencio

avelumab

Vegzelma

peginterferon alfa-2b 

belzutifan

Avzivi

Zirabev

Fotivda

Alymsys

tivozanib

Mvasi

erlotinib 

temsirolimus

capecitabine

aldesleukin

 

What is Adenocarcinoma of Renal Cells?

 

Adenocarcinoma of Renal Cells, also known as Renal Cell Carcinoma (RCC) or Kidney Adenocarcinoma, is the most common type of kidney cancer in adults. It originates in the lining of the small tubes within the kidneys, called renal tubules, and is categorized by abnormal growth and uncontrolled cell proliferation in the kidneys. RCC can metastasize (spread) to other parts of the body, including the lungs, liver, bones, and brain, making early detection and treatment crucial for better prognosis.

 

Types of Renal Cell Carcinoma

 

There are several subtypes of RCC, each with distinct characteristics:

 

1. Clear Cell Renal Cell Carcinoma (ccRCC):

   - Most common type (75-85% of RCC cases).

   - Tumor cells appear pale or clear under a microscope due to high lipid and glycogen content.

   - Tends to be more aggressive and likely to spread.

 

2. Papillary Renal Cell Carcinoma (pRCC):

   - Accounts for about 10-15% of RCC cases.

   - Tumor cells form finger-like projections, or papillae.

   - Two subtypes: Type 1 (more common and less aggressive) and Type 2 (more aggressive).

 

3. Chromophobe Renal Cell Carcinoma:

   - Makes up about 5% of RCC cases.

   - Tumor cells have a distinct appearance under a microscope with large, pale cells.

   - Generally has a better prognosis than clear cell RCC.

 

4. Collecting Duct Carcinoma:

   - Rare and aggressive subtype.

   - Originates in the ducts that collect urine in the kidney.

   - Poor prognosis due to early spread and resistance to treatment.

 

5. Unclassified RCC:

   - A rare category for tumors that do not fit into other classifications.

   - Typically more challenging to treat due to unpredictable behavior.

 

Risk Factors

 

The exact cause of RCC is not always clear, but several factors increase the risk of developing this cancer:

 

- Smoking: Increases risk significantly, with former smokers still at a heightened risk.

- Obesity: Associated with hormonal changes and increased kidney workload.

- Hypertension: Long-term high blood pressure is linked with RCC.

- Genetic Factors: Certain hereditary syndromes, like von Hippel-Lindau disease, Birt-Hogg-Dubé syndrome, and hereditary papillary RCC, increase susceptibility.

- Occupational Hazards: Exposure to substances like asbestos, cadmium, and certain herbicides.

- Chronic Kidney Disease (CKD): People with CKD or those on dialysis have a higher risk.

 

Symptoms

 

Early stages of RCC are often asymptomatic. Symptoms typically appear when the disease progresses, and may include:

 

- Hematuria (blood in urine)

- Loin pain: Persistent, dull ache in the side or lower back.

- Palpable abdominal mass: A lump in the abdomen or side.

- Unexplained weight loss and fatigue.

- Anemia or Hypercalcemia: Resulting from renal impairment.

- Fever: Intermittent, not due to infection.

 

Diagnosis

 

Several diagnostic methods are used to confirm RCC:

 

1. Imaging Studies:

   - Ultrasound: Initial scan to identify kidney masses.

   - CT Scan and MRI: Provide detailed images and help in staging.

   - PET Scan: Used if metastasis is suspected.

 

2. Biopsy: A small tissue sample is taken, though less common due to high imaging accuracy.

 

3. Blood and Urine Tests: May indicate kidney function, presence of blood in urine, and abnormalities like elevated calcium.

 

Staging

 

RCC is staged based on tumor size, location, and spread, using the TNM (Tumor, Node, Metastasis) classification:

 

- Stage I: Tumor confined to kidney, <7 cm.

- Stage II: Tumor larger than 7 cm but still confined.

- Stage III: Tumor extends into major veins or nearby lymph nodes.

- Stage IV: Cancer has spread beyond the kidney to distant organs.

 

Treatment Options

 

The approach to treatment depends on the stage, type, and overall health of the patient. Main options include:

 

1. Surgery:

   - Partial Nephrectomy: Only tumor is removed, preserving kidney function.

   - Radical Nephrectomy: Entire kidney, adrenal gland, and surrounding tissue removed; used in larger or more invasive cancers.

 

2. Ablation Therapy:

   - Radiofrequency Ablation (RFA): Heat is used to destroy cancer cells.

   - Cryoablation: Freezing technique to kill tumor cells; often for small tumors or for patients unfit for surgery.

 

3. Targeted Therapy:

   - Drugs target specific pathways (like VEGF or mTOR pathways) to restrict cancer growth and spread. Examples include Sunitinib, Pazopanib, Cabozantinib, and Everolimus.

 

4. Immunotherapy:

   - Immune Checkpoint Inhibitors (like Pembrolizumab, Nivolumab) boost the immune system to attack cancer.

   - Interleukin-2 (IL-2): Stimulates the immune response but is less commonly used due to side effects.

 

5. Radiation Therapy:

   - Primarily palliative, used to relieve symptoms when RCC has metastasized, especially in the bones.

 

Prognosis

 

The survival rate and prognosis depend on the stage at diagnosis. For early-stage, localized RCC (Stage I), the 5-year survival rate is high (approximately 90-95%). However, for advanced-stage RCC with metastasis (Stage IV), the 5-year survival rate drops significantly (around 10-20%).

 

Prevention

 

While RCC cannot always be prevented, reducing risk factors may help:

 

- Avoid smoking.

- Maintain a healthy weight and blood pressure.

- Reduce exposure to harmful substances.

- Regular check-ups, especially if there's a family history or genetic predisposition.

 

Research and Future Directions

 

Ongoing research is focused on:

 

- Genetic and Molecular Targeting: Exploring specific mutations in RCC to develop targeted treatments.

- Immunotherapy Combinations: Testing combinations of immune checkpoint inhibitors and targeted drugs.

- Biomarker Identification: Using biomarkers for early detection and personalized treatment.

 

Early detection remains critical, and there is hope that advancements in targeted therapies and immunotherapies will continue to improve outcomes for RCC patients.